Cognition-enhancing drugs.
New drugs that enhance cognition in cognitively healthy individuals present difficult public policy challenges. While their use is not inherently unethical, steps must be taken to ensure that they are safe, that they are widely available to promote equality of opportunity, and that individuals are free to decide whether or not to use them.
Mehlman
Maxwell J
MJ
Law-Medicine Center, Case Western Reserve University School of Law, 11075 East Boulevard, Cleveland, OH 44106, USA. mjm10@case.edu
D000328:Adult; D003071:Cognition / Q000187:drug effects*; D017277:Drug Approval; D004358:Drug Therapy / Q000941:ethics; D006297:Health Services Accessibility; D006801:Humans; D007880:Legislation, Drug; D018697:Nootropic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011640:Public Policy; D018570:Risk Assessment; D012449:Safety; D014481:United States; D014486:United States Food and Drug Administration
D018697:Nootropic Agents